SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 2024 ...

Financial Performance - Allogene Therapeutics, Inc. reported an adjusted loss of 43 cents per share in Q4 2023, which was better than the Zacks Consensus Estimate of a loss of 47 cents [1] - Including impairment charges, the company posted a loss of 51 cents in Q4, compared to a loss of 67 cents in the same quarter last year [2] - Revenues for the quarter were $0.02 million, missing the Zacks Consensus Estimate of $0.05 million, and down 19% year over year [2] - For the full year 2023, Allogene recorded total revenues of $0.1 million, a decrease of 39% year over year, and reported a loss of $2.09 per share, which was narrower than the previous year's loss of $2.38 [4] Expense Management - Research and development (R&D) expenses were $54.7 million, down 28% from the year-ago quarter [3] - General and administrative (G&A) expenses declined 18% year over year to $17.2 million [3] - The company anticipates operating expenses for 2024 to be around $280 million, including nearly $60 million in non-cash stock-based compensation [5] Cash Position and Market Reaction - As of December 31, 2023, Allogene had $448.7 million in cash, cash equivalents, and investments, down from $497.7 million as of September 30, 2023 [3] - Following the earnings announcement, shares of Allogene rose 5% in after-market trading on March 14, attributed to lower-than-expected operating expenses and cash burn [5] - Year to date, the stock has surged 40%, outperforming the industry growth of 0.8% [5] Pipeline Developments - In January, Allogene announced it would deprioritize two pivotal mid-stage studies, ALPHA2 and EXPAND, focusing instead on developing cema-cel as a frontline treatment for LBCL [6][7] - The company initiated start-up activities for the phase II ALPHA3 study, expected to begin in mid-2024, evaluating cema-cel for newly diagnosed LBCL patients [7] - Allogene is also exploring allogenic CAR-T cell therapies for autoimmune diseases, partnering with Arbor Biotechnologies to utilize CRISPR technology for a new candidate, ALLO-329, targeting lupus/SLE [8]

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - Executive Vice President of Research and Development and Chief Medical Officer Geoff Parker - Chief financial officer Conference Call Participants Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Brian Cheng - JPMorgan Jack Allen - Baird ...

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.51%. A quarter ago, it was expected that this immuno-oncology company would post a loss of $0.53 per share when it actually produced a loss of $0.37, delivering a surprise of 30.19%.Over the last four quarters, the ...

Allogene Therapeutics (ALLO) announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor Biotechnologies to utilize the latter’s proprietary CRISPR gene-editing technology.Allogene intends to utilize Arbor’s CRISPR technology with its own proprietary platform to develop next-generation allogeneic CAR T (AlloCAR T) therapies targeting autoimmune diseases (AID).However, neither of the companies disclosed any specific financial terms or considerations pertaining to the abov ...

Exhibit 99.1 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update • Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024 • Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Data Projected YE 2024 • ALLO-329 in Autoimmune Disease (AID): Differentiated Next-Generation CD19 Dagger Program Design ...

Table of Contents | --- | --- | --- | |-------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | _________________________________ Commission File Number | | | | Allogene Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) ____________________ ...

Allogene's AlloCAR T™ Autoimmune Disease Platform Leverages Arbor's CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. ("Arbor" ...

Core Insights - Allogene Therapeutics, Inc. (ALLO) has reached a significant support level, indicating potential for investors from a technical perspective [1] - The recent breakout of ALLO's 50-day simple moving average above its 200-day moving average signifies a "golden cross," which is a bullish indicator [1][2] - ALLO's shares have increased by 31.9% over the past four weeks, suggesting positive momentum [2] Technical Analysis - A golden cross is formed when a short-term moving average crosses above a long-term moving average, typically the 50-day and 200-day, indicating a potential bullish breakout [1] - The successful golden cross event consists of three stages: a price bottom, the crossover of moving averages, and the maintenance of upward momentum [1] Earnings Outlook - ALLO is currently rated 3 (Hold) on the Zacks Rank, indicating potential for a breakout [2] - The positive earnings outlook for the current quarter is reinforced by one upward revision in earnings estimates and no downward revisions in the past two months [2] - The Zacks Consensus Estimate for ALLO has also increased, further solidifying the bullish case for the company [2]

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/ ...